Drug Profile
Autologous cancer vaccine - Vaccinogen
Alternative Names: Active specific immunotherapy - Vaccinogen; ASI - Vaccinogen; Autologous tumour cell vaccine - Vaccinogen; Colon cancer vaccine - Intracel; OncoVAXLatest Information Update: 07 Jan 2020
Price :
$50
*
At a glance
- Originator Intracel Corporation
- Developer Intracel Corporation; National Cancer Institute (USA); Vaccinogen
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Colorectal cancer
- No development reported Malignant melanoma; Renal cancer
- Discontinued Ovarian cancer
Most Recent Events
- 07 Jan 2020 Autologous cancer vaccine is still in phase III trial for Colorectal cancer (Adjuvant therapy, Early-stage disease, Prevention of relapse) in USA (NCT02448173)
- 07 Jan 2020 No development reported - Phase-II for Colorectal cancer (Combination therapy, Adjuvant therapy) in USA (Intradermal)
- 18 Aug 2017 Vaccinogen's autologous cancer vaccine is at phase II development stage for Colorectal cancer (Combination therapy, Adjuvant therapy) in Netherlands and USA (Intradermal) (Vaccinogen website, August 2017)